Q2 2021 Earnings

Revenue

$104M+16.3% YoY

Gross Profit

$92M88.3% margin

Operating Income

$65M62.6% margin

Net Income

$391M376.1% margin

EPS (Diluted)

$2.39

QoQ Revenue Growth

+17.1%

Operating Cash Flow

$49M

Free Cash Flow

$49M

Stock-Based Comp.

$5M

Total Assets

$1.0B

Total Liabilities

$495M

Stockholders' Equity

$512M

Cash & Equivalents

$493M

Metric	Current	Year Ago	Change
Revenue	$104M	$89M	+16.3%
Gross Profit	$92M	$89M	+3.5%
Operating Income	$65M	$33M	+99.0%
Net Income	$391M	$25M	+1452.5%

Collaborative arrangements revenue

$103M98%

Sale of active pharmaceutical ingredient

$645,0001%

Collaborative arrangement, co-promotion agreements

$596,0001%

Collaborative arrangement, other agreements

$408,0000%

Collaborative arrangement, collaboration and license agreements

$200,0000%

North America

$731,00051%

Canada and Mexico

$700,00049%